TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07505069: Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors

Sponsor: Nanolattix Biotechnology Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07505069 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07505069 Rescue Dossier →